Trial Profile

A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pivekimab sunirine (Primary) ; Cytarabine; Cytarabine; Daunorubicin; Fludarabine; Hydrocortisone sodium succinate; Methotrexate; Prednisolone
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
27 Apr 2023 Planned initiation date changed from 19 Mar 2023 to 1 Aug 2023.
28 Dec 2022 Planned initiation date changed from 20 Dec 2022 to 19 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com